Integration of genome-wide association study and single-cell transcriptome analysis reveals the role of N6-methyladenosine in treatment resistance in lung cancer.
7 affiliations
- 1Department of Thoracic Surgery, Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- 2Department of Thoracic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- 3Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- 4Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, Shandong, China.
- 5Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- 6Department of Thoracic Surgery, Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. [email protected].
- 7Department of Thoracic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. [email protected].
Abstract
Background
Platinum-based chemotherapy resistance, particularly to carboplatin, is a major challenge in the treatment of non-small cell lung cancer (NSCLC). N6-methyladenosine (m6A) methylation, which regulates gene and protein expression by influencing numerous aspects of mRNA metabolism, has been implicated in NSCLC pathogenesis, but its role in treatment resistance remains unclear.Methods
We performed an innovative integrated analysis by combining genome-wide association study (GWAS) summary statistics, methylation quantitative trait loci (mQTL) data, and single-cell RNA sequencing (scRNA-seq) data from NSCLC patients. First, a transcriptome-wide association study (TWAS) using FUSION analysis was conducted to identify associations between m6A methylation sites, genes, and NSCLC by integrating m6A methylation profiles with GWAS summary statistics. Subsequently, scRNA-seq data were used to characterize NSCLC epithelial cell subpopulations and dynamically delineate the transition from treatment-sensitive to treatment-resistant states. Finally, a cross-omics correlation network was constructed by integrating the m6A and scRNA-seq datasets to identify associations between dynamic m6A modifications and carboplatin resistance.Results
Our integrated analysis identified 6 m6A sites and 9 genes significantly associated with NSCLC. ScRNA-seq analysis revealed a significant increase in the proportion of epithelial cells in the carboplatin-resistant group. Marker genes of these carboplatin-resistant epithelial cells were enriched in pathways related to glutathione metabolism, ferroptosis, and endoplasmic reticulum protein processing. The RAS oncogene family member RAB7A was identified as a critical driver of treatment resistance. MeRIP-qPCR confirmed that RAB7A mRNA carries m6A modifications, and RIP-qPCR demonstrated direct binding of the m6A reader IGF2BP2 to RAB7A transcripts. Functional assays showed that RAB7A overexpression significantly increased intracellular glutathione levels and reduced lipid ROS, indicating enhanced antioxidant capacity and ferroptosis suppression. RAB7A expression was significantly upregulated in NSCLC patients with a poor response to neoadjuvant chemotherapy. Functional validation in vitro confirmed that overexpression of RAB7A conferred carboplatin resistance in NSCLC cells.Conclusions
This study establishes a novel paradigm in which m6A-mediated gene regulation is a key contributor to chemoresistance. Furthermore, we identify RAB7A as a functionally relevant gene associated with carboplatin resistance, warranting further investigation as a candidate therapeutic target.
Related
- Multi-Omic Integration of the miRNome and Transcriptome in Dermal Fibroblasts from Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders Identifies Convergent Candidate miRNA-mRNA Regulatory Networks Linking Extracellular Matrix Remodeling and Inflammation
- Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance
- Transcriptome- and methylome-wide association studies prioritized lung cancer genes in East Asian populations
- Single-nucleus transcriptome-wide association study of human brain disorders
- Integration of Transcriptomic and Metabolomic Profiling as a Source of Insight into Key Candidate Genes and Metabolic Pathways Associated with Maize Resistance to Fusarium spp.
BibTeX
@article{miao2026integration,
title = {{Integration of genome-wide association study and single-cell transcriptome analysis reveals the role of N6-methyladenosine in treatment resistance in lung cancer.}},
author = {Huikai Miao and Chunmei Xu and Dongni Chen and Zhesheng Wen and Jiajun Du and Youfang Chen},
journal = {Cell biology and toxicology},
year = {2026},
month = aug,
doi = {10.1007/s10565-026-10244-6},
url = {https://europepmc.org/article/MED/42967964},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Integration of genome-wide association study and single-cell transcriptome analysis reveals the role of N6-methyladenosine in treatment resistance in lung cancer.
AU - Huikai Miao
AU - Chunmei Xu
AU - Dongni Chen
AU - Zhesheng Wen
AU - Jiajun Du
AU - Youfang Chen
PY - 2026
DA - 2026/08/04
JO - Cell biology and toxicology
DO - 10.1007/s10565-026-10244-6
UR - https://europepmc.org/article/MED/42967964
AB - Background Platinum-based chemotherapy resistance, particularly to carboplatin, is a major challenge in the treatment of non-small cell lung cancer (NSCLC). N6-methyladenosine (m6A) methylation, which regulates gene and protein expression by influencing numerous aspects of mRNA metabolism, has been implicated in NSCLC pathogenesis, but its role in treatment resistance remains unclear.Methods We performed an innovative integrated analysis by combining genome-wide association study (GWAS) summary statistics, methylation quantitative trait loci (mQTL) data, and single-cell RNA sequencing (scRNA-seq) data from NSCLC patients. First, a transcriptome-wide association study (TWAS) using FUSION analysis was conducted to identify associations between m6A methylation sites, genes, and NSCLC by integrating m6A methylation profiles with GWAS summary statistics. Subsequently, scRNA-seq data were used to characterize NSCLC epithelial cell subpopulations and dynamically delineate the transition from treatment-sensitive to treatment-resistant states. Finally, a cross-omics correlation network was constructed by integrating the m6A and scRNA-seq datasets to identify associations between dynamic m6A modifications and carboplatin resistance.Results Our integrated analysis identified 6 m6A sites and 9 genes significantly associated with NSCLC. ScRNA-seq analysis revealed a significant increase in the proportion of epithelial cells in the carboplatin-resistant group. Marker genes of these carboplatin-resistant epithelial cells were enriched in pathways related to glutathione metabolism, ferroptosis, and endoplasmic reticulum protein processing. The RAS oncogene family member RAB7A was identified as a critical driver of treatment resistance. MeRIP-qPCR confirmed that RAB7A mRNA carries m6A modifications, and RIP-qPCR demonstrated direct binding of the m6A reader IGF2BP2 to RAB7A transcripts. Functional assays showed that RAB7A overexpression significantly increased intracellular glutathione levels and reduced lipid ROS, indicating enhanced antioxidant capacity and ferroptosis suppression. RAB7A expression was significantly upregulated in NSCLC patients with a poor response to neoadjuvant chemotherapy. Functional validation in vitro confirmed that overexpression of RAB7A conferred carboplatin resistance in NSCLC cells.Conclusions This study establishes a novel paradigm in which m6A-mediated gene regulation is a key contributor to chemoresistance. Furthermore, we identify RAB7A as a functionally relevant gene associated with carboplatin resistance, warranting further investigation as a candidate therapeutic target.
SN - 0742-2091
SN - 1573-6822
ER -